<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Endoscopic ablation to treat <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD) is associated with a decreased incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Endoscopic spray cryotherapy (CRYO) demonstrates promising preliminary data </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To assess the safety and efficacy of CRYO in BE with HGD </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Multicenter, retrospective cohort study </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Nine academic and community centers; treatment period, 2007 to 2009 </plain></SENT>
<SENT sid="5" pm="."><plain>PATIENTS: Subjects with HGD confirmed by 2 pathologists </plain></SENT>
<SENT sid="6" pm="."><plain>Previous EMR was allowed if residual HGD remained </plain></SENT>
<SENT sid="7" pm="."><plain>INTERVENTIONS: CRYO with follow-up biopsies </plain></SENT>
<SENT sid="8" pm="."><plain>MAIN OUTCOME MEASUREMENTS: Complete eradication of HGD with persistent low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, complete eradication of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_589'>dysplasia</z:mpath> with persistent nondysplastic <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath>, and complete eradication of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Ninety-eight subjects (mean age 65.4 years, 83% male) with BE and HGD (mean length 5.3 cm) underwent 333 treatments (mean 3.4 treatments per subject) </plain></SENT>
<SENT sid="10" pm="."><plain>There were no esophageal <z:mpath ids='MPATH_81'>perforations</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>Strictures developed in 3 subjects </plain></SENT>
<SENT sid="12" pm="."><plain>Two subjects reported severe <z:hpo ids='HP_0100749'>chest pain</z:hpo> managed with oral narcotics </plain></SENT>
<SENT sid="13" pm="."><plain>One subject was hospitalized for bright red blood per rectum </plain></SENT>
<SENT sid="14" pm="."><plain>Sixty subjects had completed <z:hpo ids='HP_0000001'>all</z:hpo> planned CRYO treatments and were included in the efficacy analysis </plain></SENT>
<SENT sid="15" pm="."><plain>Fifty-eight subjects (97%) had complete eradication of HGD, 52 (87%) had complete eradication of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_589'>dysplasia</z:mpath> with persistent nondysplastic <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath>, and 34 (57%) had complete eradication of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> </plain></SENT>
<SENT sid="16" pm="."><plain>Subsquamous BE was found in 2 subjects (3%) </plain></SENT>
<SENT sid="17" pm="."><plain>LIMITATIONS: Nonrandomized, retrospective study with no control group, short follow-up (10.5 months), lack of centralized pathology, and use of surrogate outcome for decreased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="18" pm="."><plain>CONCLUSIONS: CRYO is a safe and well-tolerated therapy for BE and HGD </plain></SENT>
<SENT sid="19" pm="."><plain>Short-term results suggest that CRYO is highly effective in eradicating HGD </plain></SENT>
</text></document>